Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGI-002 in Transfusion-Dependent α-Thalassemia
NCT05851105Phase 1Recruiting
- Sponsor
- Shenzhen Hemogen Therapeutic Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HGI-002 in alpha thalassemia, sponsored by Shenzhen Hemogen Therapeutic Co., Ltd. Primary endpoints: Overall Response Rate, Adverse Events and 6 more. Started Oct 2022; status: recruiting.
02
Drugs
HGI-002
03
Conditions
alpha thalassemia
Beyond the preview
Go deeper on NCT05851105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851105.